Presentation is loading. Please wait.

Presentation is loading. Please wait.

Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions  Kenichi Suda, MD, PhD, Jihye Kim, PhD, Isao Murakami,

Published byAshlee Berry Modified over 5 years ago

Similar presentations

Presentation on theme: "Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions  Kenichi Suda, MD, PhD, Jihye Kim, PhD, Isao Murakami,"— Presentation transcript:

1 Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions  Kenichi Suda, MD, PhD, Jihye Kim, PhD, Isao Murakami, MD, PhD, Leslie Rozeboom, MS, Masaki Shimoji, MD, PhD, Shigeki Shimizu, MD, PhD, Christopher J. Rivard, PhD, Tetsuya Mitsudomi, MD, PhD, Aik-Choon Tan, PhD, Fred R. Hirsch, MD, PhD  Journal of Thoracic Oncology  Volume 13, Issue 10, Pages (October 2018) DOI: /j.jtho Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 The global unsupervised clustering analysis of expression data of all lesions analyzed. The left and right rows indicate the histology and the individual patient, respectively. LN, lymph node metastases; RML, right middle lobe of the lung; LUL, left upper lobe of the lung; AC, adenocarcinoma; SQ, squamous cell carcinoma. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Mutational and pathway analyses of lesions obtained from a never-smoking lung adenocarcinoma patient (case 1). (A) Geographic locations of analyzed lesions are shown. (B) Pathway analysis was performed with Gene Set Enrichment Analysis based on MSigDB C2 curated KEGG gene sets. (Dysregulated pathways in all lesions are summarized in Supplementary Table 1, and are excluded from the figure.) (C) Representative mutations identified in case 1. KIF5B-RET fusion was also identified in all lesions, but not in noncancerous tissue, using TopHat-Fusion on the RNA-seq. Insulin-like growth factor 2 receptor (IGF2R), major histocompatibility complex, class I, A (HLA-A), and erb-b2 receptor tyrosine kinase 2 (ERBB2) mutations were also identified as trunk mutations, whereas NF1 mutation was present only in some metastatic lesions. The phylogenetic tree was constructed using a Neighbor joining method implemented in the R phangom package, based on somatic and deleterious mutations in reliably expressed genes. The genes with asterisk indicate that somatic/deleterious mutations in those genes were identified in lesions obtained from the other lung adenocarcinoma patient (case 2). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 2 Mutational and pathway analyses of lesions obtained from a never-smoking lung adenocarcinoma patient (case 1). (A) Geographic locations of analyzed lesions are shown. (B) Pathway analysis was performed with Gene Set Enrichment Analysis based on MSigDB C2 curated KEGG gene sets. (Dysregulated pathways in all lesions are summarized in Supplementary Table 1, and are excluded from the figure.) (C) Representative mutations identified in case 1. KIF5B-RET fusion was also identified in all lesions, but not in noncancerous tissue, using TopHat-Fusion on the RNA-seq. Insulin-like growth factor 2 receptor (IGF2R), major histocompatibility complex, class I, A (HLA-A), and erb-b2 receptor tyrosine kinase 2 (ERBB2) mutations were also identified as trunk mutations, whereas NF1 mutation was present only in some metastatic lesions. The phylogenetic tree was constructed using a Neighbor joining method implemented in the R phangom package, based on somatic and deleterious mutations in reliably expressed genes. The genes with asterisk indicate that somatic/deleterious mutations in those genes were identified in lesions obtained from the other lung adenocarcinoma patient (case 2). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

5 Figure 3 Mutational and pathway analyses of lesions obtained from a lung squamous cell carcinoma patient with heavy smoking history (case 3). (A) Geographic locations of analyzed lesions. (B) Pathway analysis was performed with Gene Set Enrichment Analysis based on MSigDB C2 curated KEGG gene sets. (C) Representative mutations identified in case 3. Nuclear factor, erythroid 2 like 2 (NFE2L2) and integrin subunit beta 4 (ITGB4) mutations were identified in all lesions except for the hilar lymph node metastasis. The phylogenetic tree was constructed using a Neighbor joining method implemented in the R phangom package, based on somatic and deleterious mutations in reliably expressed genes. The genes with asterisks indicate that somatic/deleterious mutations in those genes were identified in lesions obtained from the other lung squamous cell carcinoma patient (case 4). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

6 Figure 3 Mutational and pathway analyses of lesions obtained from a lung squamous cell carcinoma patient with heavy smoking history (case 3). (A) Geographic locations of analyzed lesions. (B) Pathway analysis was performed with Gene Set Enrichment Analysis based on MSigDB C2 curated KEGG gene sets. (C) Representative mutations identified in case 3. Nuclear factor, erythroid 2 like 2 (NFE2L2) and integrin subunit beta 4 (ITGB4) mutations were identified in all lesions except for the hilar lymph node metastasis. The phylogenetic tree was constructed using a Neighbor joining method implemented in the R phangom package, based on somatic and deleterious mutations in reliably expressed genes. The genes with asterisks indicate that somatic/deleterious mutations in those genes were identified in lesions obtained from the other lung squamous cell carcinoma patient (case 4). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

7 Figure 4 The intertumor heterogeneity of potential “predictive” biomarkers for PD-1/PD-L1 targeted immunotherapy. (A) The relative expression of CD274 (PD-L1) and tumor mutation burden (the numbers of somatic/non-synonymous mutations detected) are shown. Primary lesion from each patient was marked by a dotted circle. Comparison of PD-L1 immunohistochemistry staining in the primary tumor (B), visceral pleura (C), contra-lateral lung metastasis (D), and liver metastasis (E) in case 1 is shown. PD-1, programmed death 1; PD-L1, programmed death ligand 1. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions  Kenichi Suda, MD, PhD, Jihye Kim, PhD, Isao Murakami,"

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD 

Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD 
Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma  Thomas Schneider,

Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma  Thomas Schneider,
Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape  Hawazin Faruki,

Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape  Hawazin Faruki,
RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma  Julien Faget, PhD, Caroline Contat, MS, Nadine.

RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma  Julien Faget, PhD, Caroline Contat, MS, Nadine.
Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.
PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations  Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations  Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,
Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer
Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma  Shiyong Li, BS, Yoon-La Choi, MD, PhD, Zhuolin Gong, PhD, Xiao Liu, PhD,

Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma  Shiyong Li, BS, Yoon-La Choi, MD, PhD, Zhuolin Gong, PhD, Xiao Liu, PhD,
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
ALK and ROS1 Double-Rearranged Lung Squamous Cell Carcinoma Responding to Crizotinib Treatment: A Case Report  Qiong Li, MD, Jian Wu, MD, PhD, Li-Xu Yan,

ALK and ROS1 Double-Rearranged Lung Squamous Cell Carcinoma Responding to Crizotinib Treatment: A Case Report  Qiong Li, MD, Jian Wu, MD, PhD, Li-Xu Yan,
Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens  Judith N. Müller, PhD, Markus Falk, PhD, Jatin Talwar, MSc, Nicole.

Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens  Judith N. Müller, PhD, Markus Falk, PhD, Jatin Talwar, MSc, Nicole.
Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD 

Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD 
Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?  Nicolas Girard, MD  Journal of Thoracic.

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?  Nicolas Girard, MD  Journal of Thoracic.
Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,
Transbronchial Biopsy Needle Rinse Solution Used for Comprehensive Biomarker Testing in Patients with Lung Cancer  Yuichi Sakairi, MD, PhD, Kenichi Sato,

Transbronchial Biopsy Needle Rinse Solution Used for Comprehensive Biomarker Testing in Patients with Lung Cancer  Yuichi Sakairi, MD, PhD, Kenichi Sato,
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation 

Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation 
Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Similar presentations

Ads by Google